Esomeprazole and Radiation Induced Esophagitis
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorRush University Medical Center
About this trial
Thoracic radiation therapy combined with chemotherapy (with or without immunotherapy) is the cornerstone of management in patients with locally advanced non-small cell lung cancer (NSCLC).
Eligibility criteria
Qualifiers
Patient is ≥ 18 years of age.
Patient or patient's legal representative is willing and able to provide written informed consent and HIPAA authorization prior to performance of any study related activity.
Patient is willing and able to comply with scheduled visits and treatment schedules.
Patient has histopathologically confirmed diagnosis of NSCLC clinical stage III (as per the 8th edition of American Joint Committee on Cancer Staging).
Disqualifiers
Patient has history of gastroesophageal junction or stomach cancer.
Patient has history of pre-existing severe or very severe dysphagia.
Patient has history of severe liver disease, acute or subacute systemic lupus erythematosus.
Patient has interstitial nephritis.
Trial design
Treatments tested in this trial
- Esomeprazole 40 mg
Treatment groups
48 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov